Effect of probiotic and synbiotic supplementation on inflammatory markers in health and disease status: A systematic review and meta-analysis of clinical trials. Issue 3 (March 2020)

• Record Type: Journal Article
• Authors: Kazemi, Asma; Soltani, Sepideh; Ghorabi, Sima; Keshtkar, Abbas; Daneshzad, Elnaz; Nasri, Fatemeh; Mazloomi, Seyed Mohammad
• Is Part Of: Clinical nutrition. Volume 39:Issue 3(2020)
• Page Start: 789
• Page End: 819
• Publication Date: 2020-03
• Subjects: Probiotic -- Synbiotic -- Inflammation -- Interleukin -- Cytokine -- Meta-analysis; Coef coefficient -- CRF chronic renal failure -- CRP C-reactive protein -- CVD cardiovascular disease -- IBD inflammatory bowel disease -- IBS inflammatory bowel syndrome -- IFN interferon -- IL interleukin -- LPS lipopolysaccharides -- MS metabolic syndrome -- NAFLD nonalcoholic fatty liver disease -- PCOS polycystic ovary syndrome -- PBMC peripheral blood mononuclear cell -- RA rheumatoid arthritis -- SMD Standardized mean difference -- TGF transforming growth factor -- TNF tumor necrosis factor; Critically ill -- Nutrition -- Periodicals; Diet therapy -- Periodicals; Parenteral feeding -- Periodicals; Enteral feeding -- Periodicals; Enteral Nutrition -- Periodicals; Parenteral Nutrition -- Periodicals; Metabolism -- Periodicals; Diétothérapie -- Périodiques; Alimentation parentérale -- Périodiques; Alimentation entérale -- Périodiques; Nutrition -- Périodiques; Diet therapy; Enteral feeding; Nutrition; Parenteral feeding; Electronic journals; Periodicals; Electronic journals; 615.854
• DOI: 10.1016/j.clnu.2019.04.004
• Languages: English
• ISSNs: 0261-5614

Abstract

Summary: The current systematic review and meta-analysis investigated the effect of probiotic/synbiotic on a wide range of inflammatory and anti-inflammatory markers in healthy and various disease conditions. PubMed, SCOPUS and Web of Science databases were searched. All clinical trials which investigated the effect of oral administration of probiotic or synbiotic on inflammatory markers (C-reactive protein (CRP), interleukin (IL) 1β, IL-4, IL-6, IL-8, IL-10, IL-12, tumor necrosis factor (TNF) α, interferon (IFN) γ and transforming growth factor (TGF) β) for more than one week with concurrent control groups were included. One-hundred sixty seven publications was analysed. Results were as follows: CRP decreased in healthy, metabolic disorders, inflammatory bowel disease (IBD), arthritis and critically ill condition but not in renal failure. IL-1B: no change in healthy subjects and arthritis. TNF-α: decreased in healthy, fatty liver, IBD and hepatic cirrhosis, no change in diabetes, metabolic syndrome (MS) + PCOS (polycystic ovary syndrome) and arthritis. IL-6: no change in healthy, metabolic disorders and arthritis, increased in cirrhosis and renal failure, decreased in PCOS + MS. IL-10: no change in healthy, IBD and metabolic disorders, increased in arthritis. IL-4, IL-8, IL-12, IFN-g and TGF-b: no change in healthy subjects. In conclusion, probiotic/synbiotic decreased some of the inflammatory markers. The intervention was most effective in CRP and TNF-α reduction in healthy or disease state. Moreover, the intervention decreased inflammation most effectively in the following disease conditions, respectively: IBD, arthritis, fatty liver. PROSPERO registration number: CRD42018088688.